Evidence map›Paper›PMID 33144427›Full record

ArticleIn vivo (Athens, Greece)

A Non-invasive Imageable GFP-expressing Mouse Model of Orthotopic Human Bladder Cancer.

Y U Sun, Hiroto Nishino, Ming Zhao, Kentaro Miyake, Norihiko Sugisawa, Jun Yamamoto, Yoshihiko Tashiro, Sachiko Inubushi, Kazuyuki Hamada, Guangwei Zhu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Y U SunAntiCancer, Inc., San Diego, CA, U.S.A.
Hiroto NishinoAntiCancer, Inc., San Diego, CA, U.S.A.
Ming ZhaoAntiCancer, Inc., San Diego, CA, U.S.A.
Kentaro MiyakeAntiCancer, Inc., San Diego, CA, U.S.A.
Norihiko SugisawaAntiCancer, Inc., San Diego, CA, U.S.A.
Jun YamamotoAntiCancer, Inc., San Diego, CA, U.S.A.
Yoshihiko TashiroAntiCancer, Inc., San Diego, CA, U.S.A.
Sachiko InubushiAntiCancer, Inc., San Diego, CA, U.S.A.
Kazuyuki HamadaAntiCancer, Inc., San Diego, CA, U.S.A.
Guangwei ZhuAntiCancer, Inc., San Diego, CA, U.S.A.
Hyein LimAntiCancer, Inc., San Diego, CA, U.S.A.
Robert M HoffmanAntiCancer, Inc., San Diego, CA, U.S.A. all@anticancer.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimA more realistic mouse model of bladder cancer is necessary to develop effective drugs for the disease. Tumor models enhanced by bright fluorescent-reporter genes to follow the disease in real-time would enhance the ability to accurately predict the efficacy of various therapeutics on this particularly-malignant human cancer. MATERIALS AND

methodsA highly-fluorescent green fluorescent protein (GFP)-expressing bladder cancer model was orthotopically established in nude mice using the UM-UC-3 human bladder-cancer cell line (UM-UC-3-GFP). Fragments from a subcutaneous tumor of UM-UC-3-GFP were surgically implanted into the nude mouse bladder. Non-invasive and intra-vital fluorescence imaging was obtained with a simple imaging box.

resultsThe GFP-expressing orthotopic bladder tumor was imaged in real-time non-invasively as well as intra-vitally, with the two methods correlating at r=0.99.

conclusionThis is the first non-invasive-fluorescence-imaging orthotopic model of bladder cancer and can be used for rapidly screening novel effective agents for this recalcitrant disease.

Indexed as

Urinary Bladder NeoplasmsAnimalsDisease Models, AnimalGreen Fluorescent ProteinsHumansLuminescent ProteinsMiceMice, NudeGreen Fluorescent ProteinsLuminescent ProteinsBladder cancerGFPimagingnon-invasivenude miceorthotopic

Identifiers

PMID33144427
PMCPMC7811621

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.